Press releaseGlobe Newswire
Bioxytran
BIXT · OTC
$0.0235+$0.0011 (+4.91%)TodayMarket closed ·
Prev close $0.0224
Latest news
- Press releaseGlobe Newswire
Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence
- Press releaseGlobe Newswire
Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research
- Press releaseGlobe Newswire
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
- Press releaseACCESS Newswire
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
- Press releaseACCESS Newswire
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
- Press releaseGlobe Newswire
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
- Press releaseACCESS Newswire
Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference
- Press releaseGlobe Newswire
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
- Press releaseACCESS Newswire
Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.